JAZZ Stock Surges 19% In 11-day Spree On Record Q4 Earnings Beat
Jazz Pharmaceuticals (JAZZ) – a developer and marketer of specialty pharmaceutical products for rare diseases – hit a 11-day winning streak, with cumulative gains over this period amounting to 19%. The company’s market cap has surged by about $1.9 Bil over the last 11 days and currently stands at $12 Bil.
The stock has YTD (year-to-date) return of 15.8% compared to 1.5% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Rally?
[1] Record Q4 2025 Earnings & Upbeat Guidance
- Zscaler Is Still Growing—So Why Has the Stock Been Cut in Half?
- Forget Timing the Bottom: Earn 9.9% While You Wait for ZM on Sale
- Cash Rich, Low Price – Docusign Stock to Break Out?
- Caterpillar Stock On A Winning Streak: Time To Get In Or Book Profits?
- What Could Send Palantir Technologies Stock Soaring
- Why Alphabet Stock Jumped 70%?
- Highest ever quarterly revenue of $1.2 billion
- Record 2025 revenue of $4.3 billion
- Impact: Stock jumped 11.8% post-announcement, Multiple price target hikes from analysts
Opportunity or Trap?
Below is our take on valuation.
There is a near-equal mix of good and bad in JAZZ stock given its overall Moderate operating performance and financial condition. Considering stock’s Low valuation we think it is Attractive (For details, see Buy or Sell JAZZ).
But here is the real interesting point.
You are reading about this 19% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Returns vs S&P 500
The following table summarizes the return for JAZZ stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | JAZZ | S&P 500 |
|---|---|---|
| 1D | 13.2% | 0.8% |
| 11D (Current Streak) | 19.3% | -0.3% |
| 1M (21D) | 18.3% | -0.1% |
| 3M (63D) | 11.2% | 5.2% |
| YTD 2026 | 15.8% | 1.5% |
| 2025 | 38.0% | 16.4% |
| 2024 | 0.1% | 23.3% |
| 2023 | -22.8% | 24.2% |
However, big gains can follow sharp reversals – but how has JAZZ behaved after prior drops? See JAZZ Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 39 S&P constituents with 3 days or more of consecutive gains and 27 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 15 | 18 |
| 4D | 12 | 7 |
| 5D | 9 | 1 |
| 6D | 1 | 1 |
| 7D or more | 2 | 0 |
| Total >=3 D | 39 | 27 |
Key Financials for Jazz Pharmaceuticals (JAZZ)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $3.8 Bil | $4.1 Bil |
| Operating Income | $597.6 Mil | $726.6 Mil |
| Net Income | $414.8 Mil | $560.1 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $1.0 Bil | $1.1 Bil |
| Operating Income | $219.0 Mil | $100.0 Mil |
| Net Income | $-718.5 Mil | $251.4 Mil |
While JAZZ stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.